Beyond psychedelic-assisted therapy
Advancing Psychedelic-Assisted Therapy by creating tomorrow’s therapies from today’s patient stories.
Emyria is at the forefront of efforts to make psychedelic-assisted therapies accessible to people who may benefit. But we are much more than an access point – our purpose-designed clinics offer care before, during, and after – always.
Learn more about Emyria Clinics.
Psychedelic - Assisted Therapy NEWS
- 8 JUN 2023: Emyria Receives Ethics Approval for MDMA-assisted Therapy
- 18 APR 2023: Emyria to Develop Psilocybin Therapy Care Model
- 7 MAR 2023: Emyria partners with PAX Centre for MDMA-assisted therapy
- 13 FEB 2023 Emyria secures clinical-grade MDMA supply for Aust patients
- 06 FEB 2023 - Emyria expands MDMA programs following landmark TGA decision
Ultra- Pure CBD Medicines
- Status: Phase 3 Clinical Trials
Innovative medicines targeting unmet needs, backed by real-world data.
Developed with insights from our proprietary real-world data program, EMD-RX5 is a convenient capsule medication aimed at relieving symptoms of psychological distress, like mild stress and anxiety – meaning the potential patient population is enormous.
Ultra-Pure CBD NEWS
- 24 APR 2023 - Emyria Unveils Highest Potency CBD Capsule for FDA Pathway
- 04 APR 2023 - Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5
- 30 JAN 2023 - First dosing commenced for pivotal EMD-RX5 Phase 3 trial
- 28 NOV 2022 - Emyria accepted into National Institutes of Health (NIH) Program
- 26 AUG 2022 - Emyria expands clinical sites for EMD-RX5 Phase 3 trial
- 17 MAR 2022 - Emyria launches second, Ultra-Pure CBD capsule, EMD-RX7
More novel dose forms to be announced
MDMA Inspired Medicines
- Status: Currently in Preclinical screening
Developing innovative treatments for severe psychological conditions
Emyria has exclusive access to a world-class library of over 100 MDMA analogues developed over 10 years by Dr. Matt Piggott at the University of Western Australia.
MDMA analogues have unique biochemical properties that make them attractive small molecules to develop into registered treatments for severe psychological conditions such as Post-Traumatic Stress Disorder.
UWA’s library is therefore a highly valuable drug discovery resource.
MDMA Drug Discovery NEWS
- 06 FEB 2023 - Emyria expands MDMA programs following landmark TGA decision
- 18 OCT 2022 - MDMA-analogues webinar recording
- 19 SEO 2022 - Emyria commences US preclinical program with leading neuroscience drug discovery CRO
- 18 AUG 2022: Emyria receives positive screening results for MDMA-inspired drug discovery program
- 04 AUG 2022: Preclinical studies initiated for MDMA-inspired analogues
- 18 JUL 2022: Emyria expands drug candidate library inspired by MDMA
Research & Data Programs
- Status: TGA Approved platform
Robust and ethically-sourced real-world patient data and technology-driven research programs
Our unique data platform helps us manage, monitor and improve the safety and efficacy of novel treatments for patients with unmet medical needs.
Emyria is also leading numerous innovative grant and award-winning research programs with global partners involving remote monitoring technology and psychedelic-assisted therapy.